LONG-TERM SAFETY AND EFFICACY OF PMPA (TENOFOVIR)

PMPA（替诺福韦）的长期安全性和有效性

• 批准号: 8172504
• 负责人: KOEN K VAN ROMPAY
• 金额: $ 15.21万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172504
• 关键词: Acquired Immunodeficiency Syndrome; Adenine; Animal Model; Antiviral Agents; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV Infections; Human; Institution; Macaca; Newborn Infant; Research; Research Personnel; Resources; SIV; Safety; Source; Tenofovir; Therapeutic; Toxic effect; United States National Institutes of Health; Virus Diseases; novel; pinacolyl methylphosphonic acid

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this project is to find better and safer antiviral drugs to treat HIV infection. Simian immunodeficiency virus infection of newborn and infant macaques is a useful animal model of human AIDS to evaluate novel antiviral drugs. Previously, we initiated studies to evaluate the long-term therapeutic and toxic effects of tenofovir (9-[2-(phosphonomethoxy)-propyl]adenine; PMPA).

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该项目的目的是寻找更好、更安全的抗病毒药物来治疗HIV感染。猴免疫缺陷病毒感染的新生儿和婴儿猕猴是一个有用的人类艾滋病的动物模型，以评估新的抗病毒药物。以前，我们开始研究，以评估长期的治疗和毒性作用的替诺福韦（9-[2-（膦酰甲氧基）丙基]腺嘌呤; PMPA）。